ÂÜÀòÂÒÂ×

Bernie Tobin is a 25-year veteran of the healthcare industry with his most recent role serving as President of Crescendo Bioscience, a wholly owned subsidiary of Myriad Genetics. Crescendo focused on using proteomics to deliver precision medicine to patients with autoimmune disorders.

Mr. Tobin oversaw 30%+ compounded annual growth rate (CAGR) in operating income achieved over 5 years via a series of strategic changes and operational execution across virtually all functional areas to include realignment of the senior leadership team, recruitment of new leaders, relocation of operations, changing market positioning, and launching multiple product enhancements.